Englander Institute for Precision Medicine

Publications

Found 8 results
Author Title Type [ Year(Asc)]
Filters: Author is Scherr, Douglas S  [Clear All Filters]
2023
Borregales LD, Venkat S, Calderon LPosada, Lewicki P, Flynn T, Faltas BM, Molina AM, Golombos DM, O'Malley P, Scherr DS.  2023.  A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.. Eur Urol. 84(6):604-606.
Benedetti E, Chetnik K, Flynn T, Barbieri CE, Scherr DS, Loda M, Krumsiek J.  2023.  Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.. Sci Data. 10(1):830.
Marciscano AE, Wolfe S, Zhou XKathy, Barbieri CE, Formenti SC, Hu JC, Molina AM, Nanus DM, Nauseef JT, Scherr DS et al..  2023.  Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).. BMC Cancer. 23(1):781.
2022
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M et al..  2022.  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.. JCI Insight. 7(4)
Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, Gaffney CD, Shoag J, Tu JJenny, Khani F et al..  2022.  A multidisciplinary approach to optimize primary prostate cancer biobanking.. Urol Oncol. 40(6):271.e1-271.e7.
2019
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.
Bhardwaj P, Ikeda T, Zhou XKathy, Wang H, Zheng XEmily, Giri DD, Elemento O, Verma A, Miyazawa M, Mukherjee S et al..  2019.  Supplemental estrogen and caloric restriction reduce obesity-induced periprostatic white adipose inflammation in mice.. Carcinogenesis. 40(7):914-923.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J et al..  2019.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.. Nat Commun. 10(1):2977.